2018
Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors
MINÁŘ, Luboš, Michal FELSINGER, Zdeňka ČERMÁKOVÁ, Filip ZLÁMAL, Julie BIENERTOVÁ VAŠKŮ et. al.Základní údaje
Originální název
Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors
Autoři
MINÁŘ, Luboš (203 Česká republika, garant, domácí), Michal FELSINGER (203 Česká republika, domácí), Zdeňka ČERMÁKOVÁ (203 Česká republika), Filip ZLÁMAL (203 Česká republika, domácí) a Julie BIENERTOVÁ VAŠKŮ (203 Česká republika, domácí)
Vydání
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, CLARE, ELSEVIER IRELAND LTD, 2018, 0020-7292
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30214 Obstetrics and gynaecology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 1.671
Kód RIV
RIV/00216224:14110/18:00102797
Organizační jednotka
Lékařská fakulta
UT WoS
000419300300018
Klíčová slova anglicky
Cancer antigen 125; Copenhagen Index; Human epididymis protein 4; Ovarian tumor; Risk of Ovarian Malignancy Algorithm
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 26. 3. 2019 10:37, Soňa Böhmová
Anotace
V originále
Objective To compare the Copenhagen Index (CPH-I) and the Risk of Ovarian Malignancy Algorithm (ROMA) in the differential diagnosis of ovarian tumors. Methods In a retrospective study, data were reviewed from women with ovarian tumors who attended University Hospital Brno, Czech Republic, between July 2011 and June 2015. The women were classified into the benign tumor group or malignant tumor group (borderline and malignant tumors). Serum levels of CA125 and HE4 were extracted from medical records. The two tumor indices were calculated using relevant clinical data. Results Among 267 included women, 110 had benign tumors, 42 had borderline ovarian tumors, and 115 had malignant tumors. The two indices showed similar discriminatory performance with no significant differences (P>0.05). In the differentiation of benign tumors from all stages of borderline tumor and ovarian cancer, ROMA showed a sensitivity of 71% at a specificity of 88%, whereas CPH-I showed a sensitivity of 69% at a specificity of 85%. Conclusion CPH-I is a potential tumor index that is independent of menopausal status. It might be applied as a simple alternative to ROMA in settings of basic medical care.
Návaznosti
EF15_003/0000469, projekt VaV |
| ||
LM2015051, projekt VaV |
|